Ibutilide fumarate
Modify Date: 2025-08-20 11:29:07
Ibutilide fumarate structure
|
Common Name | Ibutilide fumarate | ||
|---|---|---|---|---|
| CAS Number | 122647-32-9 | Molecular Weight | 442.61 | |
| Density | N/A | Boiling Point | 522.4ºC at 760 mmHg | |
| Molecular Formula | C22H38N2O5S | Melting Point | 112-117?C | |
| MSDS | Chinese USA | Flash Point | 269.7ºC | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of Ibutilide fumarateIbutilide Fumarate is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm.Target: Calcium ChannelIbutilide is the first 'pure' class III antiarrhythmic drug to become available. Its predominant action is prolongation of the myocardial action potential duration. Intravenous ibutilide 0.01 to 0.025 mg/kg or 1 to 2 mg successfully converted atrial flutter or fibrillation to sinus rhythm in 33 to 49% of patients in 2 placebo-controlled trials involving 439 patients with sustained arrhythmia [1]. Ibutilide appears to be an effective alternative method for rapid conversion of recent-onset AF or AFl. The drug may be particularly useful in patients who have undergone recent cardiac surgery or those who are not ideal candidates for DCC [2]. |
| Name | Ibutilide Hemifumarate |
|---|---|
| Synonym | More Synonyms |
| Description | Ibutilide Fumarate is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm.Target: Calcium ChannelIbutilide is the first 'pure' class III antiarrhythmic drug to become available. Its predominant action is prolongation of the myocardial action potential duration. Intravenous ibutilide 0.01 to 0.025 mg/kg or 1 to 2 mg successfully converted atrial flutter or fibrillation to sinus rhythm in 33 to 49% of patients in 2 placebo-controlled trials involving 439 patients with sustained arrhythmia [1]. Ibutilide appears to be an effective alternative method for rapid conversion of recent-onset AF or AFl. The drug may be particularly useful in patients who have undergone recent cardiac surgery or those who are not ideal candidates for DCC [2]. |
|---|---|
| Related Catalog | |
| References |
| Boiling Point | 522.4ºC at 760 mmHg |
|---|---|
| Melting Point | 112-117?C |
| Molecular Formula | C22H38N2O5S |
| Molecular Weight | 442.61 |
| Flash Point | 269.7ºC |
| PSA | 230.64000 |
| LogP | 10.34740 |
| Vapour Pressure | 9.71E-12mmHg at 25°C |
| InChIKey | PCIOHQNIRPWFMV-WXXKFALUSA-N |
| SMILES | CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1.CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1.O=C(O)C=CC(=O)O |
| Storage condition | Refrigerator |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 |
| Precautionary Statements | P301 + P312 + P330 |
| Hazard Codes | Xn |
| Risk Phrases | 22 |
| RIDADR | NONH for all modes of transport |
|
Efficacy and safety of ibutilide for chemical cardioversion of atrial fibrillation and atrial flutter in cancer patients.
Am. J. Med. Sci. 347(4) , 277-81, (2014) Atrial fibrillation and atrial flutter (AF/AFL) are the most common arrhythmias encountered in clinical practice. Rate versus rhythm control remains a difficult decision, especially in the acute setti... |
|
|
Brugada syndrome masked by ibutilide treatment in a patient with atrial flutter.
Cardiology 122(2) , 89-92, (2012) We present a case of Brugada syndrome in a young patient whose typical ECG pattern was 'masked' after ibutilide was administered for atrial flutter cardioversion. Ibutilide, a class III antiarrhythmic... |
|
|
Effects of ibutilide on canine cardiac pacing threshold and on induction rates of atrial fibrillation.
Cell Biochem. Biophys. 64(3) , 197-203, (2012) This study aims to observe the effects of ibutilide on canine cardiac pacing threshold and on induction rates of atrial fibrillation. Eighteen mongrel dogs were anesthetized and administrated with ibu... |
| N-(4-{4-[Ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide (2E)-but-2-enedioate (2:1) |
| (±)-N-(4-(4-(Ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide (E)-2-butenedioate (2:1) (Salt) |
| Bis[N-ethyl-N-(4-hydroxy-4-{4-[(methylsulfonyl)amino]phenyl}butyl)heptan-1-aminium] (2E)-but-2-enedioate |
| N-(4-{4-[Ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide (2E)-2-butenedioate (2:1) |
| Methanesulfonamide, N-[4-[4-(ethylheptylamino)-1-hydroxybutyl]phenyl]-, (2E)-2-butenedioate (2:1) (salt) |
| Bis[N-ethyl-N-(4-hydroxy-4-{4-[(methylsulfonyl)amino]phenyl}butyl)heptan-1-aminium]-(2E)-but-2-endioat |
| (±)-4'-(4-(Ethylheptylamino)-1-hydroxybutyl)methanesulfoanilide (E)-2-Butenedioate (2:1) |
| N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide (2E)-but-2-enedioate (2:1) (salt) |
| Bis[N-ethyl-N-(4-hydroxy-4-{4-[(methylsulfonyl)amino]phenyl}butyl)-1-heptanaminium] (2E)-2-butenedioate |
| Ibutilide hemifumarate salt |
| Ibutilide fumarate |
| UNII:9L5X4M5L6I |
| (2E)-But-2-endisäure--N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methansulfonamid(1:2) |
| acide (2E)-but-2-ènedioïque - N-(4-{4-[éthyl(heptyl)amino]-1-hydroxybutyl}phényl)méthanesulfonamide (1:2) |
| Corvert |
| Ibutilide (fumarate) |